Drugs / adriacin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02809573 Background | Aug 2016 → Jan 2019 | peripheral T-cell lymphoma, not otherwise specified | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adriacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02809573 ↗ |
| Route | Intravenous | “Adriacin is given in a 20-minute IV infusion” NCT02809573 ↗ |